Furthermore, GHK-Cu has been extensively studied for its ability to accelerate wound healing
Brighten breaks down how perimenopause and menopause shift insulin sensitivity, fat distribution, appetite, and recovery and where glucagon-like peptide-1 (GLP-1) receptor agonists (think semaglutide/Ozempic, Wegovy, liraglutide, tirzepatide as a related incretin therapy) can fit safely alongside hormone therapy, lifting, protein, and smart lab work
What We Still Dont Know Despite the growing excitement, experts are urging caution
Proceed as usual if the patient has no GI symptoms and they discontinued GLP-1s
[DOI] [PMC free article] [PubMed] [Google Scholar] 63.Baselet B., Sonveaux P., Baatout S., Aerts A